Top

Published in:

01-08-2009 | Original Article

Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: Assessing responsiveness in a model of statistical process control

Authors: M. Lindner, G. Gramer, S. F. Garbade, P. Burgard

Published in: Journal of Inherited Metabolic Disease | Issue 4/2009

Summary

Tetrahydrobiopterin (BH₄) cofactor loading is a standard procedure to differentiate defects of BH₄ metabolism from phenylalanine hydroxylase (PAH) deficiency. BH₄ responsiveness also exists in PAH-deficient patients with high residual PAH activity. Unexpectedly, single cases with presumed nil residual PAH activity have been reported to be BH₄ responsive, too. BH₄ responsiveness has been defined either by a ≥30% reduction of blood Phe concentration after a single BH₄ dose or by a decline greater than the individual circadian Phe level variation. Since both methods have methodological disadvantages, we present a model of statistical process control (SPC) to assess BH₄ responsiveness. Phe levels in 17 adult PKU patients of three phenotypic groups off diet were compared without and with three different single oral dosages of BH₄ applied in a double-blind randomized cross-over design. Results are compared for ≥30% reduction and SPC. The effect of BH₄ by ≥30% reduction was significant for groups (p < 0.01) but not for dose (p = 0.064), with no interaction of group with dose (p = 0.24). SPC revealed significant effects for group (p < 0.01) and the interaction for group with dose (p < 0.05) but not for dose alone (p = 0.87). After one or more loadings, seven patients would be judged to be BH₄ responsive either by the 30% criterion or by the SPC model, but only three by both. Results for patients with identical PAH genotype were not very consistent within (for different BH₄ doses) and between the two models. We conclude that a comparison of protein loadings without and with BH₄ combined with a standardized procedure for data analysis and decision would increase the reliability of diagnostic results.

Bernegger C, Blau N (2002) High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002. Mol Genet Metab 77: 304–313. doi:10.1016/S1096-7192(02)00171-3 PubMedCrossRef

Blau N, Erlandsen H (2004) The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol Genet Metab 82: 101–111. doi:10.1016/j.ymgme.2004.03.006 PubMedCrossRef

Burgard P, Bremer HJ, Bührdel P, et al (1999) Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr 158: 46–54. doi:10.1007/s004310051008 PubMedCrossRef

Danks DM, Cotton RGH, Schlesinger P (1976) Variant forms of phenylketonuria. The Lancet 307(7971): 1236–1237. doi:10.1016/S0140-6736(76)92179-6 CrossRef

Desviat LR, Perez B, Belanger-Quintana A, et al (2004) Tetrahydrobiopterin responsiveness: results of the BH₄ loading in 31 Spanish PKU patients and correlation with their genotype. Mol Genet Metab 83: 157–162. doi:10.1016/j.ymgme.2004.06.007 PubMedCrossRef

Fiege B, Ballhausen D, Kierat L, et al (2004) Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration. Mol Genet Metab 81: 45–51. doi:10.1016/j.ymgme.2003.09.014 PubMedCrossRef

Fiege B, Bonafé L, Ballhausen D, Baumgartner M, Thöny B, Meili D (2005) Extended tetrahydrobiopterin loading test in the diagnosis of cofactor-responsive phenylketonuria: a pilot study. Mol Genet Metab 86(Supplement 1): S91–95. doi:10.1016/j.ymgme.2005.09.014 PubMedCrossRef

Fiori L, Fiege B, Riva E, Giovannini M (2005) Incidence of BH₄-responsiveness in phenalalanine-hydroxylase deficient Italian patients. Mol Genet Metab 86(Supplement 1): S67–74. doi:10.1016/j.ymgme.2005.06.017 PubMedCrossRef

Gramer G, Garbade SF, Blau N, Lindner M (2009) Pharmacokinetics of tetrahydrobiopterin following oral loadings with three single dosages in patients with phenylketonuria. J Inherit Metab Dis 32(1): 52–57. Epub 2008 Nov 21(in press).PubMedCrossRef

Guldberg P, Rey F, Zschocke J, et al (1998) European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63: 71–79. doi:10.1086/301920 PubMedCrossRef

Güttler F, Azen C, Guldberg P, et al (1999) Relationship among genotype, biochemical phenotype, and cognitive performance in females with phenylalanine hydroxylase deficiency: report from the maternal phenylketonuria collaborative study. Pediatrics 104(2 Pt 1): 258–262. doi:10.1542/peds.104.2.258 PubMedCrossRef

Kure S, Hou DC, Ohura T, et al (1999) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. J Pediatr 135: 375–378. doi:10.1016/S0022-3476(99)70138-1 PubMedCrossRef

Lambruschini N, Perez-Duenaz B, Vilaseca MA, et al (2005) Clinical and nutritional evaluation of phenylketonuric patients on tetrahydrobiopterin monotherapy. Mol Genet Metab 86(Supplement 1): S54–S60. doi:10.1016/j.ymgme.2005.05.014 PubMedCrossRef

Langenbeck U (2008) Classifying tetrahydrobiopterin responsiveness in the hyperphenylalaninaemias. J Inherit Metab Dis 31: 67–72. doi:10.1007/s10545-007-0572-4 PubMedCrossRef

Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33: 159–174. doi:10.2307/2529310 PubMedCrossRef

Leuzzi V, Carducci C, Carducci C, et al (2006) The spectrum of phenylalanine variations under tetrahydrobiopterin load in subjects affected by phenylalanine hydroxylase deficiency. J Inherit Metab Dis 29: 38–46. doi:10.1007/s10545-006-0096-3 PubMedCrossRef

Levy H, Burton B, Cederbaum S, Scriver C (2007) Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH₄) in phenylketonuria and its use in treatment. Mol Genet Metab 92: 287–291. doi:10.1016/j.ymgme.2007.09.017 PubMedCrossRef

Lindner M, Haas D, Zschocke J, Burgard P (2001) Tetrahydrobiopterin responsiveness in phenylketonuria differs between patients with the same genotype. Mol Genet Metab 73: 104–106. doi:10.1006/mgme.2001.3168 PubMedCrossRef

Lindner M, Steinfeld R, Burgard P, Schulze A, Mayatepek E, Zschocke J (2003) Tetrahydrobiopterin sensitivity in German patients with mild phenylalanine hydroxylase deficiency. Hum Mutat 21: 400. doi:10.1002/humu.9117 PubMedCrossRef

Lutz P, Schmidt H, Batzler U (1990) Study design and description of patients. Eur J Pediatr 149(Supplement 1): S5–12. doi:10.1007/BF02126292 PubMedCrossRef

MacDonald A (2000) Diet and compliance in phenylketonuria. Eur J Pediatr 159: S136–141. doi:10.1007/PL00014375 PubMedCrossRef

MacDonald A, Harris G, Rylance G, Asplin DA, Booth IW (1997) Abnormal feeding behaviours in phenylketonuria. J Hum Nutr Diet 10(3): 163–170. doi:10.1046/j.1365-277X.1997.00050.x CrossRef

Matalon R, Koch R, Michals-Matalon K, et al (2004) Biopterin responsive phenylalanine hydroxylase deficiency. Genet Med 6: 27–32. doi:10.1097/01.GIM.0000108840.17922.A7 PubMedCrossRef

Matalon R, Michals-Matalon K, Koch R, Grady J, Tyring S, Stevens RC (2005) Response of patients with phenylketonuria in the US to tetrahydrobiopterin. Mol Genet Metab 86(Supplement 1): S17–21. doi:10.1016/j.ymgme.2005.06.024 PubMedCrossRef

Montgomery DG (2005) Introductions to statistical Statistical quality Quality controlControl, 5th edition. New York:John Wiley & Sons, New York.

Muntau AAC, Röschinger W, Habich M, et al (2002) Tetrahydrobiopterin as an alternative treatment for mild phenylkentonuria. N Engl J Med 347: 2122–2132. doi:10.1056/NEJMoa021654 PubMedCrossRef

Niederwieser A, Curtius HC, Viscontini M, Schaub J, Schmidt H (1979) Phenylketonuria variants. The Lancet 313(8115): 550. doi:10.1016/S0140-6736(79)90966-8 CrossRef

Niederwieser A, Ponzone A, Curtius HC (1985) Differential diagnosis of tetrahydrobiopterin deficiency. J Inherit Metab Dis 8(Supplement 1): 34–38. doi:10.1007/BF01800657 PubMedCrossRef

Perez-Duenas B, Vilaseca MA, Mas A, et al (2004) Tetrahydrobiopterin responsiveness in patients with phenylketonuria. Clin Biochem 37: 1083–1090. doi:10.1016/j.clinbiochem.2004.09.005 PubMedCrossRef

Schulze A, Lindner M, Kohlmüller D, Olgemöller K, Mayatepek E, Hoffmann GF (2003) Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatr Pediatrics 111(6 Pt 1): 1399–406. doi:10.1542/peds.111.6.1399

Scriver CR, Kaufman S (2001) Hyperphenylalaninemias: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 1667–1724.

Spaapen LJ, Rubio-Gozalbo ME (2003) Tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency, state of the art. Mol Genet Metab 78: 93–99. doi:10.1016/S1096-7192(02)00229-9 PubMedCrossRef

Weglage J, Funders B, Ullrich K, Rupp A, Schmidt E (1996) Psychosocial aspects in phenylketonuria. Eur J Pediatr 155: S101–104. doi:10.1007/PL00014225 PubMedCrossRef

Weglage J, Grenzebach M, von Teeffelen-Heithoff A, et al (2002) Tetrahydrobiopterin responsiveness in a large series of phenylketonuria patients. J Inherit Metab Dis 25: 321–322. doi:10.1023/A:1016514727870 PubMedCrossRef

Zurflüh MR, Giovannini M, Fiori L, et al (2005) Screening for tetrahydrobiopterin deficiencies using dried blood spots on filter paper. Mol Genet Metab 86(Supplement 1): S96–103. doi:10.1016/j.ymgme.2005.09.011 PubMedCrossRef

Zurflüh MR, Zschocke J, Lindner M, Feillet F, Chery C, Burlina A (2008) Molecular genetics of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Hum Mutat 29: 167–75. doi:10.1002/humu.20637 PubMedCrossRef

Title: Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: Assessing responsiveness in a model of statistical process control
Authors: M. Lindner
G. Gramer
S. F. Garbade
P. Burgard
Publication date: 01-08-2009
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 4/2009
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-009-1070-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Blood phenylalanine concentrations in patients with PAH-deficient hyperphenylalaninaemia off diet without and with three different single oral doses of tetrahydrobiopterin: Assessing responsiveness in a model of statistical process control

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 4/2009

Long-term needs of adult patients with organic acidaemias: outcome and prognostic factors

Coenzyme Q10 is decreased in fibroblasts of patients with methylmalonic aciduria but not in mevalonic aciduria

Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop

Serum phenylalanine concentrations in patients post trauma and burn correlate to neopterin concentrations

Sleep-related breathing in children with mucopolysaccharidosis

Retinitis pigmentosa and mucopolysaccharidosis type II: an extremely attenuated phenotype

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page